Expression of Transglutaminase-2 (TGM2) in the Prognosis of Female Invasive Breast Cancer

Overview

Journal BJC Rep

Publisher Nature Portfolio

Date 2024 Nov 8

PMID 39516660

Authors

Fiona M Blows

H Raza Ali

Wei Cope

Paul D P Pharoah

Claire V S Pike

Elena Provenzano

Peter Coussons

Affiliations

Soon will be listed here.

Abstract

Background: Transglutaminase 2 (TGM2) is a protein expressed in several isoforms in both intra- and extra-cellular tissue compartments. It has multiple functions that are important in cancer biology and several small studies have suggested expression of TGM2 in breast cancers is associated with a poorer prognosis. The aim of this study was to evaluate the role of intra-cellular and extra-cellular TGM2 expression in breast cancer and to determine whether there were any differences by hormone receptor status.

Methods: We carried out TGM2 immunostaining of tissue micro-arrays comprising 2169 tumour cores and scored these for both intra- and extra-cellular and expression.

Results: Intra-cellular (tumour cell) TGM2 positivity was associated with a better prognosis (HR = 0.74, 95% CI 0.59-0.92) with a larger effect stronger in hormone-receptor-negative cases (HR = 0.56, 95% CI 0.37-0.85). Extra-cellular (stromal) TGM2 expression was associated with a poorer prognosis (HR = 1.47, 95% CI 1.06-2.03) with a stronger association in hormone-receptor-positive cases (HR = 1.60, 95% CI 1.09-2.34).

Conclusion: Tissue compartment and hormone receptor status differences in the effect of TGM2 expression on clinical outcomes of breast cancer may reflect the different functions of TGM2.

References

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Jones R, Kotsakis P, Johnson T, Chau D, Ali S, Melino G . Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ. 2005; 13(9):1442-53. DOI: 10.1038/sj.cdd.4401816. View

Sarkar N, Clarke D, WAELSCH H . An enzymically catalyzed incorporation of amines into proteins. Biochim Biophys Acta. 1957; 25(2):451-2. DOI: 10.1016/0006-3002(57)90512-7. View

Assi J, Srivastava G, Matta A, Chang M, Walfish P, Ralhan R . Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence. PLoS One. 2013; 8(9):e74437. PMC: 3772876. DOI: 10.1371/journal.pone.0074437. View

Fok J, Mehta K . Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells. Apoptosis. 2007; 12(8):1455-63. DOI: 10.1007/s10495-007-0079-3. View

Antonyak M, Jansen J, Miller A, Ly T, Endo M, Cerione R . Two isoforms of tissue transglutaminase mediate opposing cellular fates. Proc Natl Acad Sci U S A. 2006; 103(49):18609-14. PMC: 1654133. DOI: 10.1073/pnas.0604844103. View

Kumar S, Donti T, Agnihotri N, Mehta K . Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways. Int J Cancer. 2014; 134(12):2798-807. DOI: 10.1002/ijc.28623. View

Grootes I, Keeman R, Blows F, Milne R, Giles G, Swerdlow A . Incorporating progesterone receptor expression into the PREDICT breast prognostic model. Eur J Cancer. 2022; 173:178-193. PMC: 10412460. DOI: 10.1016/j.ejca.2022.06.011. View

Candido Dos Reis F, Wishart G, Dicks E, Greenberg D, Rashbass J, Schmidt M . An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res. 2017; 19(1):58. PMC: 5440946. DOI: 10.1186/s13058-017-0852-3. View

10.

Wakefield J . A Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am J Hum Genet. 2007; 81(2):208-27. PMC: 1950810. DOI: 10.1086/519024. View

11.

Gundemir S, Colak G, Tucholski J, Johnson G . Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta. 2011; 1823(2):406-19. PMC: 3265640. DOI: 10.1016/j.bbamcr.2011.09.012. View

12.

Oh K, Ko E, Kim H, Park A, Moon H, Noh D . Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res. 2011; 13(5):R96. PMC: 3262209. DOI: 10.1186/bcr3034. View

13.

Mangala L, Fok J, Zorrilla-Calancha I, Verma A, Mehta K . Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene. 2006; 26(17):2459-70. DOI: 10.1038/sj.onc.1210035. View

14.

Siziopikou K, Cobleigh M . The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2006; 16(1):104-7. DOI: 10.1016/j.breast.2006.09.003. View

15.

Shinde A, Paez J, Libring S, Hopkins K, Solorio L, Wendt M . Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche. Oncogenesis. 2020; 9(2):16. PMC: 7018754. DOI: 10.1038/s41389-020-0204-5. View

16.

Xu D, Xu N, Sun L, Yang Z, He M, Li Y . TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway. BMC Cancer. 2022; 22(1):1267. PMC: 9724448. DOI: 10.1186/s12885-022-10364-2. View

17.

Brown K . Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype. Breast Cancer Res Treat. 2012; 137(2):329-36. DOI: 10.1007/s10549-012-2351-7. View

18.

Philp C, Siebeke I, Clements D, Miller S, Habgood A, John A . Extracellular Matrix Cross-Linking Enhances Fibroblast Growth and Protects against Matrix Proteolysis in Lung Fibrosis. Am J Respir Cell Mol Biol. 2017; 58(5):594-603. DOI: 10.1165/rcmb.2016-0379OC. View